IMPEDIMED LIMITED — Capital/Financing Update 2018

Oct 11, 2018

==> picture [230 x 54] intentionally omitted <==

12 October 2018

ASX ANNOUNCEMENT

ImpediMed Completes Asset Sale of XiTRON Technologies, Inc.

Brisbane, Australia and Carlsbad, CA, - ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), is pleased to announce that it has agreed to the divestiture of XiTRON Technologies, Inc. to Vitrek, LLC.

Under the terms of the agreement, Vitrek, LLC has agreed to pay US$500,000 for the net assets of the test and measurement business, subject to any working capital adjustment. ImpediMed has received a perpetual world-wide license for all technology and know-how related to the medical segment of the business, and agreed to provide certain transition services to Vitrek, LLC as part of the transaction. The divestment is not subject to the satisfaction of any conditions precedent and the transaction was signed and completed today.

Richard Carreon, Managing Director and CEO of ImpediMed says, “We are very pleased to have completed this transaction so that we can fully focus the organization on the opportunities we have with our SOZO[®] digital health platform. I would like to thank the XiTRON employees for their dedication and hard work to support the business over the last few years.”

Richard Carreon Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.